Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Am J Gastroenterol. 2021 Aug 1;116(8):1738-1740. doi: 10.14309/ajg.0000000000001287.
Direct-acting antivirals (DAAs) are curative treatments for hepatitis C. However, initiation of these treatments requires adequate healthcare access. Coronavirus 2019 (COVID-19) resulted in restrictions to healthcare services in March 2020. We examined the impact of COVID-19 on the number of individuals dispensed DAAs.
This is a cross-sectional study examining the number of individuals dispensed DAAs in Ontario, Canada, from 2018 to 2020. Time-series models determined the impact of healthcare restrictions on DAA dispensations.
Healthcare restrictions resulted in a 49.3% decrease in DAA dispensations (P = 0.026).
COVID-19-related healthcare restrictions significantly affected access to DAAs. Studies exploring the long-term effects on reduced treatment are needed.
直接作用抗病毒药物（DAAs）是丙型肝炎的治愈性治疗方法。然而，这些治疗的启动需要足够的医疗保健服务。2020 年 3 月，新型冠状病毒 2019（COVID-19）导致医疗服务受到限制。我们研究了 COVID-19 对 DAA 分发数量的影响。
这是一项横断面研究，调查了 2018 年至 2020 年期间加拿大安大略省分发 DAA 的人数。时间序列模型确定了医疗保健限制对 DAA 配药的影响。
医疗保健限制导致 DAA 配药减少 49.3%（P = 0.026）。
与 COVID-19 相关的医疗保健限制极大地影响了 DAA 的可及性。需要研究减少治疗的长期影响。
